<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lipsitz YY</submitter><funding>Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada</funding><funding>Canada Research Chairs</funding><funding>CIHR</funding><pagination>6369-6374</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6016797</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>115(25)</volume><pubmed_abstract>The development of cell-based therapies to replace missing or damaged tissues within the body or generate cells with a unique biological activity requires a reliable and accessible source of cells. Human pluripotent stem cells (hPSC) have emerged as a strong candidate cell source capable of extended propagation in vitro and differentiation to clinically relevant cell types. However, the application of hPSC in cell-based therapies requires overcoming yield limitations in large-scale hPSC manufacturing. We explored methods to convert hPSC to alternative states of pluripotency with advantageous bioprocessing properties, identifying a suspension-based small-molecule and cytokine combination that supports increased single-cell survival efficiency, faster growth rates, higher densities, and grea</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Modulating cell state to enhance suspension expansion of human pluripotent stem cells.</pubmed_title><pmcid>PMC6016797</pmcid><funding_grant_id>CGS-D</funding_grant_id><funding_grant_id>Tier 1</funding_grant_id><pubmed_authors>Zandstra PW</pubmed_authors><pubmed_authors>Yin T</pubmed_authors><pubmed_authors>Hanna JH</pubmed_authors><pubmed_authors>Lipsitz YY</pubmed_authors><pubmed_authors>Woodford C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Modulating cell state to enhance suspension expansion of human pluripotent stem cells.</name><description>The development of cell-based therapies to replace missing or damaged tissues within the body or generate cells with a unique biological activity requires a reliable and accessible source of cells. Human pluripotent stem cells (hPSC) have emerged as a strong candidate cell source capable of extended propagation in vitro and differentiation to clinically relevant cell types. However, the application of hPSC in cell-based therapies requires overcoming yield limitations in large-scale hPSC manufacturing. We explored methods to convert hPSC to alternative states of pluripotency with advantageous bioprocessing properties, identifying a suspension-based small-molecule and cytokine combination that supports increased single-cell survival efficiency, faster growth rates, higher densities, and grea</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jun</publication><modification>2026-05-06T06:47:31.249Z</modification><creation>2019-03-26T23:43:48Z</creation></dates><accession>S-EPMC6016797</accession><cross_references><pubmed>29866848</pubmed><doi>10.1073/pnas.1714099115</doi></cross_references></HashMap>